Review of Contemporary Philosophy I
SSN: 1841-5261, e-ISSN: 2471-089X
Vol 23 (2), 2024
pp. 7422 - 7433

Personalized Medicine in Radiation Oncology: A Comprehensive Overview of Current Strategies and Emerging Trends

[1] Yahya Mohammed Mutawam, [2]Mohammed Galawi Alotaibi,[3]Dr.Dina Idarous Misky,[4]Ibrahim Ali Saleh,[5]Waleed Ibrahim Alrasini,[6]Albandri Hamood Hassan Alhazmi,[7]Ali Jaber Hazzazi,[8]Yahya Jaber Hazazi,[9]Bashaer Abdullah Hakami,[10]Ahmed Mahmoud Mrshod Al-Hamdi,[11]Mariam Abdulhameed Almohammedsaleh,[12]Ali Jaber Hazzazi,[13]Yahya Jaber Hazazi,[14]Bashaer Abdullah Hakami,

[1]Ksa, Ministry Of Health

[2]Ksa, Ministry Of Health, Ruwidat Alard General Hospaital

[3]Ksa, Ministry Of Health, Hera General Hospital Makkah

[4]Ksa, Ministry Of Health, Sabya General Hospital

[5]Ksa, Ministry Of Health, Prince Sultan Military Medical City

[6]Ksa, Ministry Of Health, Sabya General Hospital

[7]Ksa, Ministry Of Health, King Fahad Centeral Hospital Jazan

[8]Ksa, Ministry Of Health, King Fahad Centeral Hospital Jazan

[9]Ksa, Ministry Of Health, King Fahad Centeral Hospital Jazan

[10]Ksa, Ministry Of Health, Umluj General Hospital

[11]Ksa, Ministry Of Health, King Faisal Hospital

[12]Ksa, Ministry Of Health, King Fahad Centeral Hospital Jazan

[13]Ksa, Ministry Of Health, King Fahad Centeral Hospital Jazan

[14]Ksa, Ministry Of Health, King Fahad Centeral Hospital Jazan

Abstract

The incorporation of genomics and precision medicine has paved the way for a new landscape in oncology research where extremely personalized therapeutic approaches are now capable of being designed depending on the genetic and phenotypic characteristics of patients. Radiogenomics, an evolving new science, is the combination of radiological imaging and genomic information that provides a non-invasive view into the molecular underpinnings of tumor biology. This paper presents a comprehensive overview of radiogenomics, tracing its origins from traditional radiology, describing its methods, and evaluating its breakthrough applications in cancer therapy. Through the application of quantitative imaging features—tumor shape, texture, and metabolic activity—and associating them with genomic signatures, radiogenomics enhances cancer diagnosis sensitivity, enhances prognostic assessment, and optimizes treatment planning. We present the end-to-end radiogenomics process from image acquisition and feature extraction to building predictive models and emphasize its translational relevance to numerous cancer types, such as lung, breast, and brain cancers. Aside from its promise, radiogenomics is also encumbered by difficulties such as the need for standard protocols, lack of data, and difficulty in combining multi-omics datasets. This article outperforms these difficulties and proposes future directions, such as the integration

of artificial intelligence and multi-center efforts to drive the clinical translation of radiogenomics and anchor it in precision oncology.

Keywords: Personalized medicine, radiation, oncology, current strategies, radiogenomics, review

Received: 04 October 2024 Revised: 23 November 2024 Accepted: 10 December 2024

1. Introduction

The incorporation of precision medicine into cancer provides an unprecedented seismic shift in cancer therapy as it incorporates the specific genetic and phenotypic characteristics of a single patient. While prior therapies used similar treatment protocols across broad populations of patients, precision medicine provides a "one-size-fits-one" approach of using vast amounts of presented genotypic and phenotypic patient data, enabling clinicians to develop methods of achieving maximum benefit and eliciting the least amount of unnecessary side effects (Collins & Varmus, 2015). This most recent transitional phase was precipitated by rapid advances in genomic technologies, which allow clinicians to identify specific molecular alterations—genetic mutations, epigenetic modifications, and environmental exposures—that create a patient's signature for their cancer (Smith et al., 2020). In oncology, where cancer appears as an extremely heterogeneous disease with rich molecular dynamics, this patient-oriented practice is particularly revolutionary.

Cancer is a heterogeneous disease arising from a multitude of genetic and epigenetic alterations. For example, genetic mutations can be classified as nucleotide substitutions, insertions, deletions, and chromosomal rearrangements, and they stimulate oncogenes or silence tumor suppressors, causing uncontrolled growth (Hanahan & Weinberg, 2011). In turn, epigenetic modifications impact gene expression through DNA methylation, histone modifications, and changes in the expression of non-coding RNA and thus play a role in oncogenesis (Jones & Baylin, 2019). Traditional diagnostic methods, such as tissue biopsies and pathology, have allowed for the detection and functional analysis of either molecular driver as we know them today. However, there are significant limitations to these traditional approaches: they are invasive, do not provide an accurate state of the heterogeneity of the tumor in time and space, and are not suitable for serial assessment of disease progression or response to treatment (Gerlinger et al., 2018). These constraints underscore the value of novel, non-invasive technology that addresses the goals of precision medicine.

2. Radiogenomics

Radiogenomics is an innovative meeting point between radiology and genomics, offering a non-invasive means to untangle the molecular characteristics of tumors by using imaging data. By extracting quantitative imaging features from clinical imaging modalities such as CT, MRI, and PET and associating them with genomic profiles through radiogenomics, they create a dynamic, integrated image of tumor biology (Lambin et al., 2017). This overlap transforms imaging from a fixed diagnostic tool to a powerful vehicle for the detection of biomarkers that can enhance cancer diagnosis, predict prognosis, and guide individualized therapy (Gillies et al., 2016).

The power of radiogenomics is that it has the ability to link measurable tumor phenotypes—shape, texture, and metabolic rates—to intrinsic genetic signatures without reliance on invasive procedures. For instance, irregular tumor margins or heterogeneous textures on imaging may be linked with specific mutations, those in the EGFR or KRAS genes, and provide actionable insights into potential therapeutic response (Aerts et al., 2014). This study seeks to elucidate the nature of radiogenomics, detail its pipeline from image acquisition to predictive modeling, and examine its applications to various forms of cancer, such as lung, breast, and brain cancers. Besides, it touches on the barriers to its broader adoption, such as the lack of established imaging protocols and the lack of well-annotated large databases, and offers suggestions for the future in an effort to integrate radiogenomics into precision oncology practice.

3. Precision Medicine and the Molecular Basis of Cancer

Precision medicine aims at tailoring treatments to each patient's individualized biological profile, a notion that revolutionized cancer treatment (Dagogo-Jack & Shaw, 2018). In essence, cancer is a genomic instability disorder, appearing from the accumulation of genetic aberrations resulting in the disruption of normal cellular homeostasis. The types of aberrations include point mutations, insertions, deletions, and larger chromosomal rearrangements that activate oncogenes like RAS or MYC or inactivate tumor suppressor genes like TP53 or RB1 (Hanahan & Weinberg, 2011). In addition to genetic alterations, epigenetic changes can also promote tumorigenesis. Epigenetic modifications can silence or increase gene expression (increase permissiveness for malignancy) through hypermethylation of promoter regions, histone deacetylation or acetylation, and disruption of microRNAs (Jones & Baylin, 2019).

Decades of genome research have indicated the key oncogenic drivers that are diagnostic and therapeutic targets. Genetic mutations in genes such as KRAS, EGFR, and ALK have now been established as biomarkers of response to targeted agents, e.g., tyrosine kinase inhibitors, in tumours such as non-small cell lung cancer (Herbst et al. 2018). Historically, these genetic datasets were obtained from invasive biopsies of a single portion of the tumour at a single time point, which, while a snapshot of the mutational landscape of the particular tumour, did not represent the spatial and temporal heterogeneity of the malignancy. Radiogenomics offers a promising answer by linking imaging-derived features with such molecular alterations, enabling non-invasive monitoring of disease advancement, anticipation of treatment outcomes, and tailoring of therapeutic approaches (Grossmann et al., 2017). The combination strengthens the paradigm of precision medicine, making it the basis of modern oncology.

4. The Shift from Radiology to Radiogenomics

Radiology has been a part of cancer management for over a century, providing clinicians with qualitative information regarding tumor characteristics such as size, shape, and anatomical location (Fass, 2008). Radiological interpretation previously relied mainly upon the individual experience of radiologists, who evaluated qualitative patterns for the diagnosis and stage of disease (Kumar et al., 2012). The development of radiomics was a significant step, taking the field in the direction of an objective, data-driven approach. Radiomics applies high-throughput computational strategies to extract hundreds of quantitative features—pixel intensity, texture heterogeneity, and morphological features—derived from imaging data, yielding a richer characterization of tumor phenotypes (Lambin et al., 2012).

Radiogenomics makes this radiomics platform more comprehensive by joining these quantitative imaging features with genomic data, building the bridge between the macroscopic visual image of the tumor and its microscopic genetic makeup (Rutman & Kuo, 2009). This expansion has been fueled by fast-paced technology advancement: high-resolution imaging modalities, next-generation sequencing, and sophisticated computational platforms that can manage and process gigantic multi-omics data (Bodalal et al., 2019). For example, radiogenomics might reveal how a tumor's abnormal borders on an MRI would be linked to malignant gene mutations, providing prognostic data that could not be uncovered by traditional radiology alone (Diehn et al., 2008). By transforming radiology into an inductive and predictive science, radiogenomics gives entry to a new era in oncology where imaging not only detects cancer but reads its molecular drives.

5. Technological Foundations of Radiogenomics

The exciting field of radiogenomics is expanding quickly due to advancements in imaging, genomics, and computational analysis that help bring together previously disparate data sets to enhance our understanding of tumour biology. In genomics, ultrahigh-throughput technologies such as next-generation sequencing (NGS), microarrays, and mass spectrometry have revolutionized tumour profiling, allowing researchers to analyse genetic and epigenetic mutations with extraordinary detail (Goodwin et al., 2016). Simultaneously, new imaging modalities have enhanced the visualization of tumour phenotypes quickly and non-invasively. Multimodality imaging technologies such as positron-emission tomography-computed tomography (PET-CT), single-photon emission computed tomography (SPECT), and multiparametric

magnetic resonance imaging (MRI) provide anatomical and functional detail regarding tumors with cellularity, vascularity, and metabolic activity characteristics (Bomanji et al., 2001). For example, diffusion-weighted MRI (DW-MRI) captures tumor cellularity and density non-invasively in order to monitor response to therapy, while fluorodeoxyglucose (FDG)-PET assesses metabolic activity for assessing tumor angiogenesis, metabolic behavior, and response to therapy and disease progression (Padhani et al., 2009; Juweid & Cheson, 2006).

Radiogenomics leans on computer resources, as machine learning and deep learning, the workhorses of radiogenomics, enable the processing of incomprehensibly complex high-dimensional data (Hosny et al., 2018). Any number of different machines learning techniques, ranging from random forests to neural networks, can detect specific and refined relationships between imaging and genomic data, and in turn, allow the identification of new biomarkers that are prognostic for predicted clinical outcomes (LeCun et al., 2015). Specialized software platforms, such as PyRadiomics, Computational Environment for Radiation Research (CERR), and IBEX, can make computing radiomic features affordable, further grouping them into morphology (i.e., volume, sphericity), intensity (i.e., gray-level distribution), and dynamic (i.e., temporal contrast enhancement) strategies (van Griethuysen et al., 2017; Deasy et al., 2003; Zhang et al., 2015). These traits quantify tumor properties that reflect underlying biological processes, such as intratumoral heterogeneity and aggressiveness, to enable the development of prediction models for the guidance of precision oncology (Parmar et al., 2015).

6. Radiogenomics Workflow and Methodology

Radiogenomics is an innovative approach in precision oncology, synergistically combining medical imaging and genomic data to generate actionable insight into tumor biology. This multi-step process transforms raw imaging data into quantifiable features that are translated to genomic profiles or clinical outcomes and enable non-invasive predictions of genetic mutations, treatment responses, and prognosis of a patient. The radiogenomics pipeline consists of five interconnected steps: image acquisition, pre-processing, tumor segmentation, feature extraction, and predictive modeling (Figure 1). Each step in the process requires meticulous attention to detail in identifying the reproducibility and reliability of results, since errors at any step will taint the entire analysis. By linking imaging phenotypes to molecular genotypes in an ordered fashion, radiogenomics offers a beautiful mechanism for personalizing cancer, reducing reliance on invasive diagnostics, and, above all, the capacity to sense the dynamic dynamics of tumors (Aerts et al., 2014). This section provides an in-depth description of every phase, its aim, approach, and significance in propelling precision oncology.



Figure 1. Radiogenomics workflow overview.

6.1. Image Acquisition

The radiogenomics pipeline begins with image acquisition, a critical phase establishes quality and data range for future application in analyses. Quality imaging is paramount to record the tumor characteristics—size, shape, texture, and metabolic activity—which will be later matched with genomic alterations. Modality selection is rendered specific to the cancer type and the biology being inquired about, and each modality has its own unique advantages. Computed Tomography (CT) scan, for example, produces highly detailed images of anatomical structure and thus has a unique niche in characterizing tumor morphology in neoplasms like lung or pancreatic cancer (Kumar et al., 2012). Magnetic Resonance Imaging (MRI) surpasses traditional soft tissue contrast and functional imaging and is therefore the ultimate modality for a spectrum of cancers, including prostate, breast, and brain cancer. Imaging protocols such as diffusion weighted imaging (DWI) portray tumor cellularity, and dynamic contrast-enhanced (DCE) MRI allow for vascular parameter quantification, yielding information on the dynamics of the tumor microenvironment (Padhani et al., 2009). Positron Emission Tomography (PET), especially in hybrid imaging with computed tomography (CT) as PET-CT, is a method of monitoring the metabolic function following the administration of radiotracers such as fluorodeoxyglucose (FDG) that have unique uses, especially for the assessment of tumor aggressiveness and response to therapy for neoplasms such as lymphoma and head and neck cancer (Miles et al., 2012).

The use of multimodal imaging is rapidly growing (e.g., PET-MRI) as an effort to best exploit the biological information. PET-MRI utilizes a single PET and MRI session to allow the metabolic PET data to integrate anatomy and functional information from MRI and create a comprehensive dataset for radiogenomic investigations. PET-MRI can measure glucose metabolism and the tissue microstructure in glioblastoma studies, allowing for an n-dimensional description of the tumor (Bailey et al., 2015). Functional imaging methods further augment this phase. DWI-MRI quantifies tissue water diffusion, which is related to tumor density and aids in treatment planning, while FDG-PET quantifies metabolic changes reflecting disease growth or treatment efficacy (Gillies et al., 2016). The strategic selection of imaging modalities is therefore essential as it dictates the tumor features that can be quantified and related to genomic data in the follow-up process.

6.2. Pre-Processing Techniques

Raw imaging data, though informative, is typically compounded by inconsistencies due to scanner variation, image protocol variation, or patient-specific reasons such as motion or contrast uptake. These difficulties are addressed via pre-processing by taking the data to a common denominator so that it becomes sufficient for strong and reproducible analysis. This is done through a series of primary techniques. Image registration aligns images of different modalities (e.g., PET and CT) or time points (e.g., pre- and post-treatment images) so they are anatomically identical, a necessity for longitudinal tumor growth analyses of tumors, such as in the surveillance of lung cancer. Intensity normalization normalizes differences in pixel/voxel intensity scales caused by scanner settings or contrast agents, so features are intersubject and interinstitution comparable. Filter techniques, such as Gaussian filters to denoise or edge-detection filters to enhance the edges of tumors, enhance the signal-to-noise ratio and hence improve the accuracy of follow-up analysis (Zwanenburg et al., 2020).

Pre-processing is very important for minimizing artifacts that can obscure biological signals, e.g., scanner noise or patient motion during imaging. However, heterogeneity of pre-processing between studies has long marred radiogenomics research. To address this, the Image Biomarker Standardization Initiative (IBSI) has come up with standardized protocols and reference values for normalization, filtering, and other pre-processing operations, which foster reproducibility and enable comparability across studies (Zwanenburg et al., 2016). These efforts are vital in making radiogenomics an off-the-shelf clinical application from a research tool, making imaging data consistent and reliable for later feature extraction and modeling.

6.3. Tumor Segmentation

Segmentation of the tumor is an important part of the radiogenomics process in that it is employed to define the tumor within the imaging data so that the region of interest (ROI) to be analyzed can be discerned. Segmentation properly enables subsequent feature extraction to be focused on the tumor proper and not on surrounding tissues. Errors at this stage will lead to wrong features and inaccurate predictions, and hence segmentation plays a crucial role in determining the success of the workflow (Hatt et al., 2017). Three primary techniques are used, each striking a balance between accuracy, speed, and scalability. Manual segmentation relies on the skillful radiologists to delineate the tumor boundaries from image slices, which can be very accurate but labor-intensive and prone to inter-observer variation—various experts may mark the same tumor slightly differently, affecting consistency (Kumar et al., 2012). Semi-automatic segmentation combines human expertise with computer processes, in which a clinician sets initial points, and an algorithm continuously refines the edges based on image characteristics like intensity gradients, reducing effort and variability (Veeraraghavan et al., 2018). Machine learning and particularly deep learning architectures like convolutional neural networks (CNNs) power automatic segmentation, quickly and accurately handling large sets of data, and hence it is the most suitable choice for high-throughput studies. These approaches, having been trained on annotated images, detect tumor borders at a high degree of accuracy (Kamnitsas et al., 2017).

Modern computer platforms such as 3D Slicer and DeepMind enhance segmentation by incorporating the deep learning feature and user interfaces, accelerating the process (Fedorov et al., 2012; Gibson et al., 2018). For instance, in a study on breast cancer, CNN segmentation can automatically delineate tumors in hundreds of MRI images in a matter of hours, which would take weeks manually. Study size, available resources, and required accuracy determine the segmentation method, but automation is increasingly favored for its speed and reproducibility, paving the way for large-scale radiogenomic studies.

6.4. Feature Extraction

Following tumor segmentation, feature extraction quantifies its imaging features to provide a radiomic features dataset that describes the tumor's phenotype. They are the imaging-genomics bridge that defines biological properties like heterogeneity, vascularity, or aggressiveness with the potential to be linked to genetic mutations. Radiomic features can be categorized into several types. Morphological features measure the physical form of the tumor, for example, volume, surface area, sphericity, or compactness—abnormal shape might indicate invasive growth related to specific mutations. Intensity-based features analyze the voxel/pixel intensity profile within the ROI, for example, mean intensity, skewness, or entropy, where high entropy might indicate necrosis or cellularity of the tumor. Texture characteristics measure spatial frequency patterns of intensity, and intratumoral heterogeneity is revealed by measurements such as gray-level co-occurrence matrices (GLCM) or gray-level run-length matrices (GLRLM). It is generally associated with aggressive biology or treatment resistance (Davnall et al., 2012). Dynamic imaging characteristics, acquired from time-series imaging like DCE-MRI or PET, track contrast uptake or metabolism over time, with early washout of contrast indicating high vascularity and thus a marker of tumor angiogenesis (Miles et al., 2012).

Sophisticated platforms like PyRadiomics, CERR, and IBEX normalize feature extraction to make calculations consistent across studies and reduce variability (van Griethuysen et al., 2017; Apte et al., 2018; Zhang et al., 2015). In a case of lung cancer research, for example, PyRadiomics might extract over 1,000 features from a single CT scan, creating a high-dimensional dataset that captures the tumor's complexity. These features form the foundation of downstream analyses, enabling researchers to uncover imaging phenotypes and genomic or clinical associations.

6.5. Predictive Modeling

The final step of the radiogenomics pipeline is predictive modeling, where radiomic features are used to create models predictive of genomic profiles or clinical endpoints, such as survival, response to treatment, or status for genetic mutations. The method engages statistical and machine learning techniques to identify

meaningful associations in high-dimensional complex radiomic data. Two leading approaches are utilized. Exploratory analyses contrast a broad range of imaging features with genomic variables to discover novel associations, and statistical controls like the false discovery rate (FDR) are required to prevent spurious positives due to multiple testing (Benjamini & Hochberg, 1995). Techniques like PCA can be used to reduce data by extracting informative patterns in features. Hypothesis-driven research, in contrast, focuses on pre-specified relationships, e.g., do specific MRI texture features predict KRAS mutations in colorectal cancer, leveraging prior biological insight to inform analysis (Konstantinidis et al., 2019).

Machine learning techniques, including support vector machines (SVMs), random forests, and neural networks, are applied most frequently to model the non-linear relationships in radiomic data (Parmar et al., 2015). For instance, a random forest model might combine PET-CT texture and dynamic information to predict EGFR mutation status in lung cancer patients as a non-invasive alternative to biopsy. Model performance is rigorously tested by using techniques such as k-fold cross-validation or external cohorts to determine generalizability and clinical utility (Vickers & Elkin, 2006). These confirmed models make radiogenomics a tangible clinical instrument, making predictions of genetic mutations (e.g., IDH1 in gliomas), therapy responsiveness, or patient survival possible without invasive testing, thus opening the door for individualized cancer treatment (Aerts et al., 2014).

7. Applications of Radiogenomics Across Cancer Types

Lung cancer is still one of the leading causes of cancer-related mortality worldwide, and it represents a high amount of genetic heterogeneity that complicates treatment decisions. Multiple investigations of genetic alterations in EGFR and KRAS are trying to find principles for guiding NSCLC treatment decisions with targeted agents such as tyrosine kinase inhibitors (Herbst et al., 2018). Radiogenomics has emerged as a groundbreaking technology for this purpose, relying on imaging data to non-invasively predict such alterations. Radiomic CT-derived texture and shape feature signatures have been shown to accurately predict the EGFR mutation status of NSCLC patients and enable clinicians to stratify patients for target therapy based on this without requiring invasive biopsies (Aerts et al., 2014). Similarly, PET imaging by fluorodeoxyglucose (FDG) also provides texture characteristics linked with KRAS mutations and information regarding tumor aggressiveness with an input to treatment planning (Yip et al., 2017). These radiogenomic approaches can potentially not only allow for less use of invasive techniques but also allow for repeat testing and capture changes in lung tumor behavior over time. As radiogenomics seeks to link imaging features to molecular signatures, it can enhance specificity in lung cancer therapy by providing patient-specific therapeutic options that maximize clinical outcomes.

Breast cancer is a heterogeneous cancer, with different biological and molecular subtypes (luminal, HER2-enriched, and triple negative) that provide information on treatment and prognosis. Radiogenomics is important to this area as it correlates MRI characteristics with molecular subtypes and genetic signatures (e.g. BRCA1/2 alterations, associated with familial breast cancer) (Li et al, 2019). Quantitative radiomic signatures from MRI are able to distinguish between breast cancer subtypes using features, or component characteristics, such as tumor heterogeneity, irregularity of edges, and contrast enhancement patterns. For instance, heterogeneous patterns of texture from dynamic contrast-enhanced (DCE)-MRI of the tumor have been seen in association with triple-negative breast cancer, which is an aggressive subtype with fewer treatment options (Braman et al., 2017). While radiogenomics can provide information on tumor characterization, it can also be relevant for predicting response to immunotherapy. Changes in imaging biomarkers (e.g., peritumoral texture) are associated with the presence of immune cells and provide the opportunity to predict a patient's immune checkpoint inhibitor response in a non-invasive manner (Wu et al., 2019). This capability enhances the clinical usefulness of radiogenomics in breast cancer as a non-invasive decision-making tool for personalized treatment decision-making, tracking therapy response, and managing treatment for patients with different molecular phenotypes.

Gliomas, the most common type of primary brain cancers, are highly genetically heterogeneous tumors, with IDH1 mutation and MGMT promoter methylation as key prognostic markers and therapeutic targets (Louis et al., 2016). The concept of radiogenomics has transformed glioma management as it links anatomic

MRI-based characteristics to genetic mutations, therefore providing a non-invasive alternative to serial biopsy. For example, T2-weighted or FLAIR MR sequence texture characteristics have shown strong correlations with IDH1 mutations, which are favorable prognostics with low-grade gliomas (Ellingson et al., 2013). Similarly, there are radiomic features from contrast-enhanced MRI that predict MGMT methylation status, a biomarker of sensitivity to alkylating agents such as temozolomide (Kickingereder et al., 2016). Through these correlations, MDs and oncologists can non-invasively stratify their patients into personalized care cohorts. By depicting glioma's spatial-temporal heterogeneity, radiogenomics can be used to delineate longitudinal disease evolution and treatment response. Radiogenomics offers a progressive approach to brain tumor management that aligns with the principles of precision oncology.

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are commonly diagnosed liver cancers that often pose different genetic and clinical challenges for clinicians. Radiogenomics has emerged as very promising in these cancers, using CT and MRI signatures to predict important prognostic and therapeutic variables. For example, in HCC, radiomic signatures such as tumor margin irregularity and texture heterogeneity have been assessed to predict microvascular invasion, a key factor in predicting tumor behavior and recurrence risk following surgical resection or transplantation (Banerjee et al., 2015). In ICC, radiologic features such as contrast-enhanced CT patterns of enhancement relate to genomic profiles, which identify actionable therapy targets like FGFR2 fusions or IDH1 mutations (Konstantinidis et al., 2019). These processes allow for the better risk stratification in order to provide personalized treatment recommendations – surgical resection, ablation, or targeted agents – in the context of tumor molecular and imaging characteristics. By providing a non-invasive method of assessing tumor biology, radiogenomics ultimately provides a platform for precision medicine in liver cancer that targets patient-centered clinical outcomes via personalized risk stratification and treatment recommendations.

8. Challenges in Radiogenomics

One of the biggest challenges for broader implementation of radiogenomics is the absence of standardized image acquisition protocols, tumor segmentation algorithms, and feature extraction methodologies. Each institutional imaging hardware, scanner parameters, and analysis software will result in significant variability that impedes the reproducibility of radiogenomic results (Traversi et al., 2020). Variability in CT contrast protocols during pre-scan preparation for an imaging study or variability in the selection of MRI sequence parameters affects the image's extracted radiomic features, allowing variation in results across institutions. There is also significant variability when it comes to segmentation, whether completed manually, semi-automatically or automatically, all of which will change the reliability of feature extraction and create challenges for cross-study comparisons. To help overcome issues relating to variability, there have been initiatives like the Image Biomarker Standardization Initiative (IBSI), that published guidelines to enable defining radiomic features in a standard way, and also provided image pre-processing and analysis protocols that all imaging sites can follow to help ensure consistency and reproducibility (Zwanenburg et al, 2020). This is important to build trust in radiogenomics models and participate into the clinical workflow seamlessly.

Radiogenomics studies typically deal with retrospective datasets with small populations that raise issues of overfitting and reduced generalizability. Small cohorts have been known to miss the complete spectrum of tumor heterogeneity and lead to highly performing models on training sets but not on new groups (Gillies et al., 2016). Retrospective studies are also subject to selection bias because they will include only patients with available imaging and genomic data, resulting in biased conclusions. In order to mitigate these limitations of retrospective studies, there needs to be an urgent fund of prospective trials at scale and multicenter studies with diverse patient populations using standardized data collection systems. Open-access data repositories like The Cancer Imaging Archive (TCIA) are an important resource by providing access to carefully curated imaging and clinical data sets so that researchers can try models on larger cohorts (Clark et al., 2013). Collaborative effort on the construction of large, heavily annotated databases will be essential to enhance the robustness and usability of radiogenomic models (Lambin et al., 2017).

The complexity of radiogenomic models is one of the key barriers towards their utilization in clinical settings. Highly complex high-dimensional radiomic features and highly complex machine learning models could complicate biological interpretation of outcomes, making it challenging for clinicians to interpret and trust these models (Reyes et al., 2020). A model used to predict EGFR mutation status from radiomic features numbering in the hundreds may lack transparent, intuitive meaning for a practicing oncologist, and its uptake into decision-making workflows will be challenging. Furthermore, radiogenomics needs to integrate seamlessly with current clinical infrastructure, such as electronic health records and imaging systems, to be effective in routine practice. To address many of the aforementioned challenges, it is vital to create software that clinicians will embrace while producing interpretable outcomes, such as visual dashboards or biomarker scores that can readily be explained to patients (Shimizu & Nakayama, 2021). Training and education activities that prepare clinicians to engage with radiogenomics and their application in clinical practice, and to promote the collaborative relationship between radiologists, oncologists, and data scientists will also be important for greater uptake.

9. Future Perspective

Standardization is the foundation of radiogenomics' future, and ongoing initiatives are laying the groundwork for more regular and reproducible studies. The Image Biomarker Standardization Initiative (IBSI) and the Quantitative Imaging Biomarkers Alliance (QIBA) are leading the way in standardizing image acquisition, feature extraction, and analysis protocols, controlling scanner and institution variability (Sullivan et al., 2015; Zwanenburg et al., 2020). Moreover, reporting items such as the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) enhance quality and transparency in studies and ensure radiogenomic research is undertaken to sufficient scientific standards (Moons et al., 2015). Consequently, they will facilitate the generalizability of radiogenomic models across centers, generate confidence in the clinical utility of these models, and expedite their translation into clinical practice.

In addition, emerging imaging methods, such as chemical exchange saturation transfer (CEST) or blood oxygen level-dependent (BOLD) MRI, will increase radiogenomic databases with new attributes of tumor biology, including pH or oxygen status (Padhani et al., 2009). Integration of multi-omics approaches - genomic/ proteomic/ metabolomic data with imaging, will further improve understanding of complex biological relationships (Jiang et al., 2019). Concurrently, innovation in artificial intelligence and deep learning is changing the landscape of radiogenomics, as these approaches automate feature extraction, reduce reliance on hand-designed features, and demonstrate new relationships that may fail to be seen without them (Hosny et al., 2018). Nevertheless, the AI models must marry complexity with interpretability to ensure clinical usability (Bi et al., 2019). The successful construction of sufficiently large, high-quality datasets will be important for the training of high-quality AI models; this highlights the importance of multi-institutional and collaborative research.

The ultimate long-term goal of radiogenomics is to be implemented in the clinical setting and ideally used to inform real-time clinical decision making for cancer care. Multicenter large-scale clinical trials will be required to validate radiogenomic models against conventional diagnostic methods, such as biopsies, and demonstrate their value added in terms of accuracy and outcomes (Topol, 2019). Development of clinician interfaces that are simple to use—e.g., decision support tools that present radiogenomic predictions in naturalistic form—will bridge the divide between practice and research. International collaborations, supported by institutions like the Radiological Society of North America (RSNA) and global cancer research networks, will drive these efforts by promoting data sharing and method harmonization. Once the challenges we've mentioned above have been solved, radiogenomics can become a key aspect of precision oncology, assisting with early detection, planning treatments, and tracking and monitoring response.

10. Conclusion

Radiogenomics has been a revolutionary step forward in precision oncology, providing a non-invasive, low-cost solution to understand the intricacies of tumor biology. Radiogenomics offers insights into whole-tumor heterogeneity with quantitative imaging characteristics, providing predictive and prognostic

information important to personalized medicine, unlike traditional biopsies, which offer thin slices of tumor genetics. Radiogenomics is relevant across cancers, from EGFR mutation prediction in lung cancer to immunotherapy modulation in breast cancer to genetic marker stratification of gliomas. Although fraught with potential, radiogenomics is confronted with standardization barriers, data limitations, and the need for clinician-readable resources. Nevertheless, ongoing endeavors in standardization, imaging, and AI technology development, and collaborative research initiatives pose to dismantle these challenges. With the growth of radiogenomics, it can potentially revolutionize cancer care, nicely filling in clinical practices to enable earlier detection, improved treatment planning, and enhanced patient care through data-driven, patient-specific methods.

References

1. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. *New England Journal of Medicine*, 372(9), 793-795.
2. Smith, A. D., et al. (2020). Precision medicine in oncology: A review. *Journal of Clinical Oncology*, 38(15), 1735-1745.
3. Jones, P. A., & Baylin, S. B. (2019). The epigenomics of cancer. *Cell*, 128(4), 683-692.
4. Gerlinger, M., et al. (2018). Intratumor heterogeneity and branched evolution. *New England Journal of Medicine*, 366(10), 883-892.
5. Lambin, P., et al. (2017). Radiomics: The bridge between medical imaging and personalized medicine. *Nature Reviews Clinical Oncology*, 14(12), 749-762.
6. Gillies, R. J., et al. (2016). Radiomics: Images are more than pictures, they are data. *Radiology*, 278(2), 563-577.
7. Aerts, H. J., et al. (2014). Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. *Nature Communications*, 5, 4006.
8. Fass, L. (2008). Imaging and cancer: A review. *Molecular Oncology*, 2(2), 115-152.
9. Kumar, V., et al. (2012). Radiomics: The process and the challenges. *Magnetic Resonance Imaging*, 30(9), 1234-1248.
10. Rutman, A. M., & Kuo, M. D. (2009). Radiogenomics: Creating a link between molecular diagnostics and diagnostic imaging. *European Journal of Radiology*, 70(2), 232-241.
11. Diehn, M., et al. (2008). Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. *Proceedings of the National Academy of Sciences*, 105(13), 5213-5218.
12. Bodalal, Z., et al. (2019). Radiomics: A critical step towards integrated diagnostics. *Insights into Imaging*, 10(1), 84.
13. Dagogo-Jack, I., & Shaw, A. T. (2018). Tumour heterogeneity and resistance to cancer therapies. *Nature Reviews Clinical Oncology*, 15(2), 81-94.
14. Mazurowski, M. A. (2015). Radiogenomics: What it is and why it is important. *Journal of the American College of Radiology*, 12(8), 862-866.
15. Grossmann, P., et al. (2017). Defining the biological basis of radiomic phenotypes in lung cancer. *eLife*, 6, e23421.
16. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell*, 144(5), 646-674.
17. Herbst, R. S., et al. (2018). The biology and management of non-small cell lung cancer. *Nature*, 553(7689), 446-454.

18. Rizzo, S., et al. (2016). CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. *European Radiology*, 26(1), 32-42.

19. Li, H., et al. (2019). MRI radiomics signatures for predicting breast cancer recurrence. *Radiology*, 290(2), 382-391.

20. Yip, S. S., et al. (2017). Associations between somatic mutations and metabolic imaging phenotypes in NSCLC. *Journal of Nuclear Medicine*, 58(2), 227-233.

21. Braman, N. M., et al. (2017). Intratumoral and peritumoral radiomics for predicting response to neoadjuvant chemotherapy in breast cancer. *Breast Cancer Research*, 19(1), 57.

22. Wu, J., et al. (2019). Radiogenomics of breast cancer using dynamic contrast-enhanced MRI. *Cancer Imaging*, 19(1), 48.

23. Louis, D. N., et al. (2016). The 2016 WHO classification of CNS tumors. *Acta Neuropathologica*, 131(6), 803-820.

24. Ellingson, B. M., et al. (2013). Probabilistic radiographic atlas of glioblastoma phenotypes. *American Journal of Neuroradiology*, 34(3), 533-540.

25. Kickingereder, P., et al. (2016). Radiomic profiling of glioblastoma. *Radiology*, 280(3), 880-889.

26. Banerjee, S., et al. (2015). A CT radiogenomic biomarker predicts microvascular invasion in HCC. *Hepatology*, 62(3), 792-800.

27. Konstantinidis, I. T., et al. (2019). Radiogenomic analysis of intrahepatic cholangiocarcinoma. *Annals of Surgical Oncology*, 26(9), 2768-2776.

28. Traversi, G., et al. (2020). Radiomics in oncology: A review focusing on NSCLC. *Frontiers in Oncology*, 10, 568579.

29. Zwanenburg, A., et al. (2020). The image biomarker standardization initiative. *Radiology*, 295(2), 328-338.

30. Moons, K. G., et al. (2015). TRIPOD: Explanation and elaboration. *Annals of Internal Medicine*, 162(1), W1-W73.

31. Clark, K., et al. (2013). The Cancer Imaging Archive (TCIA). *Journal of Digital Imaging*, 26(6), 1045-1057.

32. Reyes, M., et al. (2020). On the interpretability of AI in radiology. *Radiology: Artificial Intelligence*, 2(3), e190043.

33. Shimizu, H., & Nakayama, K. (2021). Artificial intelligence in oncology. *Cancer Science*, 112(4), 1452-1460.

34. Sullivan, D. C., et al. (2015). Metrology standards for quantitative imaging biomarkers. *Radiology*, 277(3), 813-825.

35. Bailey, D. L., et al. (2015). Quantitative SPECT imaging and clinical applications. *Journal of Nuclear Medicine*, 56(1), 83-87.

36. Padhani, A. R., et al. (2009). Diffusion-weighted MRI as a cancer biomarker. *Neoplasia*, 11(2), 102-125.

37. Jiang, Y., et al. (2019). Multi-omics analysis in cancer. *Briefings in Bioinformatics*, 20(6), 2220-2234.

38. Hosny, A., et al. (2018). Artificial intelligence in radiology. *Nature Reviews Cancer*, 18(8), 500-510.

39. Bi, W. L., et al. (2019). AI in cancer imaging: Clinical challenges and applications. *CA: A Cancer Journal for Clinicians*, 69(2), 127-157.

40. Topol, E. J. (2019). High-performance medicine: The convergence of human and AI. *Nature Medicine*, 25(1), 44-56.

41. Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate. *Journal of the Royal Statistical Society: Series B*, 57(1), 289-300.

42. Parmar, C., et al. (2015). Machine learning methods for quantitative radiomic biomarkers. *Scientific Reports*, 5, 13087.

43. Vickers, A. J., & Elkin, E. B. (2006). Decision curve analysis. *Medical Decision Making*, 26(6), 565-574.

44. van Griethuysen, J. J. M., et al. (2017). Computational radiomics system. *Cancer Research*, 77(21), e104-e107.

45. Apte, A. P., et al. (2018). 3D Slicer as an image computing platform. *Magnetic Resonance Imaging*, 36(2), 132-141.

46. Zhang, L., et al. (2015). IBEX: An open infrastructure software platform for radiomics. *Medical Physics*, 42(3), 1341-1353.

47. Davnall, F., et al. (2012). Assessment of tumor heterogeneity by CT texture analysis. *European Journal of Radiology*, 81(12), 342-348.

48. Miles, K. A., et al. (2012). Texture analysis of portal vein CT for predicting tumor aggressiveness. *Radiology*, 264(2), 444-453.

49. Veeraraghavan, H., et al. (2018). Appearance-constrained semi-automatic segmentation from DCE-MRI. *Scientific Reports*, 8(1), 4838.

50. Kamnitsas, K., et al. (2017). Efficient multi-scale 3D CNN for brain lesion segmentation. *Medical Image Analysis*, 36, 61-78.

51. Fedorov, A., et al. (2012). 3D Slicer for the Quantitative Imaging Network. *Magnetic Resonance Imaging*, 30(9), 1323-1341.

52. Gibson, E., et al. (2018). NiftyNet: A deep-learning platform for medical imaging. *Computer Methods and Programs in Biomedicine*, 158, 113-122.

53. Hatt, M., et al. (2017). Characterization of PET/CT images using texture analysis. *European Journal of Nuclear Medicine and Molecular Imaging*, 44(1), 151-165.

54. Zhou, M., et al. (2018). Radiomics in brain tumors. *Journal of Magnetic Resonance Imaging*, 48(3), 593-606.

55. Farshidfar, F., et al. (2017). Integrative genomic analysis of cholangiocarcinoma. *Cell Reports*, 18(11), 2780-2794.

الطب الشخصي في علاج الأورام بالإشعاع: نظرة شاملة حول الاستراتيجيات الحالية والاتجاهات الناشئة

الملخص

أدت إضافة علم الجينوم والطب الدقيق إلى تمهيد الطريق أمام مشهد جديد في أبحاث الأورام، حيث أصبح من الممكن الآن تصميم أساليب علاجية شديدة التخصيص بناءً على الخصائص الجينية والظاهرية للمرضى. يُعد الراديو جينوميكس (Radiogenomics) علماً ناشئاً يجمع بين التصوير الشعاعي والمعلومات الجينومية، مما يوفر رؤية غير جراحية للأساس الجزيئي لبيولوجيا الورم. تقدم هذه الورقة نظرة شاملة عن الراديو جينوميكس، متتبعةً أصوله من الأشعة التقليدية، واصفةً أساليبه، وتقيم تطبيقاته الهامة في علاج السرطان. من خلال تطبيق ميزات التصوير الكمي مثل شكل الورم، وملمسه، ونشاطه الأيضي، وربطها بالتوقيعات الجينومية، يعزز الراديو جينوميكس حساسية تشخيص السرطان، ويحسن تقييم النتائج، ويُحسن تخطيط العلاج. نقدم العملية الكاملة للراديو جينوميكس من الحصول على الصورة واستخراج الميزات، إلى بناء نماذج تنبؤية، ونؤكد على أهميتها الانتقالية لأنواع متعددة من السرطان مثل سرطان الرئة والثدي والدماغ. بالإضافة إلى وعوده الواعدة، يواجه الراديو جينوميكس تحديات مثل الحاجة إلى بروتوكولات معيارية، ونقص البيانات، وصعوبة دمج مجموعات البيانات متعددة الأوميكس. تتجاوز هذه المقالة تلك الصعوبات وتقترح اتجاهات مستقبلية، مثل دمج الذكاء الاصطناعي والجهود متعددة المراكز لدفع الترجمة السريرية للراديو جينوميكس وتثبيته في طب الأورام الدقيق.

الكلمات المفتاحية :الطب الشخصي، الإشعاع، علم الأورام، الاستراتيجيات الحالية، الراديو جينوميكس، مراجعة.